News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
69,442 Results
Type
Article (1930)
Company Profile (2)
Press Release (67510)
Section
Business (21465)
Career Advice (9)
Deals (4553)
Drug Development (8165)
FDA (1805)
Job Trends (800)
News (37026)
Policy (3566)
Tag
Academia (91)
Alliances (8126)
Alzheimer's disease (121)
Antibody-drug conjugate (ADC) (10)
Approvals (1825)
Artificial intelligence (12)
Bankruptcy (8)
Best Places to Work (585)
Biosimilars (15)
Breast cancer (15)
Cancer (168)
Career advice (9)
Cell therapy (18)
Clinical research (6955)
Collaboration (68)
COVID-19 (185)
C-suite (9)
Data (145)
Diabetes (11)
Diagnostics (596)
Drug discovery (12)
Duchenne muscular dystrophy (7)
Earnings (7520)
Events (6911)
Executive appointments (40)
FDA (1909)
Funding (45)
Gene therapy (14)
GLP-1 (40)
Government (235)
Healthcare (1075)
Infectious disease (190)
Inflammatory bowel disease (15)
Intellectual property (8)
IPO (1619)
Job creations (240)
Job search strategy (9)
Layoffs (6)
Legal (950)
Liver cancer (15)
Lung cancer (27)
Lymphoma (10)
Manufacturing (25)
Medical device (1113)
Medtech (1114)
Mergers & acquisitions (3005)
Metabolic disorders (33)
Neuroscience (155)
NextGen: Class of 2025 (219)
Non-profit (61)
Northern California (115)
Obesity (15)
Ovarian cancer (7)
Pancreatic cancer (6)
Parkinson's disease (12)
Patents (13)
People (4939)
Phase I (1891)
Phase II (2909)
Phase III (2644)
Pipeline (66)
Postmarket research (242)
Preclinical (655)
Radiopharmaceuticals (22)
Rare diseases (22)
Real estate (598)
Regulatory (2564)
Research institute (91)
Schizophrenia (6)
Series A (11)
Southern California (112)
Startups (421)
United States (1016)
Vaccines (20)
Date
Last 7 days (40)
Last 30 days (184)
Last 365 days (3150)
2025 (332)
2024 (3253)
2023 (3814)
2022 (7016)
2021 (6373)
2020 (5876)
2019 (3875)
2018 (3012)
2017 (3561)
2016 (3174)
2015 (4030)
2014 (3020)
2013 (2600)
2012 (2776)
2011 (2902)
2010 (2663)
Location
Africa (79)
Arizona (7)
Asia (21257)
Australia (2425)
California (264)
Canada (195)
China (124)
Connecticut (12)
Europe (12356)
Florida (15)
Illinois (16)
India (8)
Japan (58)
Maryland (66)
Massachusetts (185)
Minnesota (25)
New Jersey (146)
New York (118)
North Carolina (53)
Northern California (115)
Pennsylvania (38)
South America (105)
Southern California (112)
Texas (18)
Utah (10)
Virginia (15)
69,442 Results for "kamada ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America
January 23, 2025
·
9 min read
Business
Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Kamada Ltd. announced that it will release financial results for the first quarter ended March 31, 2024, prior to the open of the U.S. financial markets on Wednesday, May 8, 2024.
May 1, 2024
·
2 min read
Press Releases
Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025
January 9, 2025
·
11 min read
Press Releases
Kamada to Present at the Stifel 2024 Healthcare Conference
November 5, 2024
·
3 min read
Pharm Country
Kamada Issues 2024 CEO Letter to Shareholders
Kamada Ltd., a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, issued a Letter to Shareholders from Amir London, Chief Executive Officer.
March 6, 2024
·
18 min read
Business
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
Kamada Ltd. announced financial results for the three months and year ended December 31, 2023.
March 6, 2024
·
21 min read
Business
Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance
Kamada Ltd., a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced financial results for three months ended March 31, 2024.
May 8, 2024
·
18 min read
Business
Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024Company to Host Conference Call at 8:30am ET
Kamada Ltd. announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2023, as well as provide 2024 financial guidance, prior to the open of the U.S. financial markets on Wednesday, March 6, 2024.
February 28, 2024
·
3 min read
Kedrion Announces an Eight-Year Extension of the Distribution Agreement With Kamada in the US for KEDRAB®
Kedrion Biopharma announces the execution of a binding memorandum of understanding with Kamada Ltd., an Israeli commercial stage global biopharmaceutical company and leader in the specialty plasma-derived field, for the amendment and the 8-year extension of the KEDRAB® US distribution agreement between the two companies.
December 7, 2023
·
5 min read
Pharm Country
Kamada Provides Corporate Update on its Israel Operations
Kamada Ltd. today announced that while circumstances in Israel are evolving, the Company continues to conduct its business operations in Israel with no effect on business continuity, and its global supply of products is not expected to be interrupted.
October 10, 2023
·
4 min read
1 of 6,945
Next
